Literature DB >> 30796820

Interleukin 2 is an Upstream Regulator of CD4+ T Cells From Visceral Leishmaniasis Patients With Therapeutic Potential.

Shashi Bhushan Chauhan1, Rebecca Faleiro2,3, Rajiv Kumar4,5, Susanna Ng2, Bhawana Singh1, Om Prakash Singh1, Siddharth Sankar Singh1, Fiona Amante2, Fabian de Labastida Rivera2, Madhukar Rai1, Jaya Chakravarty1, David Sacks6, Susanne Nylen7, Shyam Sundar1, Christian Engwerda2.   

Abstract

Control of visceral leishmaniasis (VL) caused by Leishmania donovani requires interferon-γ production by CD4+ T cells. In VL patients, antiparasitic CD4+ T-cell responses are ineffective for unknown reasons. In this study, we measured the expression of genes associated with various immune functions in these cells from VL patients and compared them to CD4+ T cells from the same patients after drug treatment and from endemic controls. We found reduced GATA3, RORC, and FOXP3 gene expression in CD4+ T cells of VL patients, associated with reduced Th2, Th17, and FOXP3+CD4+ T regulatory cell frequencies in VL patient blood. Interleukin 2 (IL-2) was an important upstream regulator of CD4+ T cells from VL patients, and functional studies demonstrated the therapeutic potential of IL-2 for improving antiparasitic immunity. Together, these results provide new insights into the characteristics of CD4+ T cells from VL patients that can be used to improve antiparasitic immune responses.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 Leishmania donovanizzm321990 ; CD4+ T cells; IL-2; visceral leishmaniasis

Mesh:

Substances:

Year:  2019        PMID: 30796820      PMCID: PMC6775044          DOI: 10.1093/infdis/jiz074

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  46 in total

Review 1.  Organ-specific immune responses associated with infectious disease.

Authors:  C R Engwerda; P M Kaye
Journal:  Immunol Today       Date:  2000-02

2.  IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani.

Authors:  Maira G R Pitta; Audrey Romano; Sandrine Cabantous; Sandrine Henri; Awad Hammad; Bouréma Kouriba; Laurent Argiro; Musa el Kheir; Bruno Bucheton; Charles Mary; Sayda Hassan El-Safi; Alain Dessein
Journal:  J Clin Invest       Date:  2009-07-13       Impact factor: 14.808

3.  Administration of recombinant interleukin-2 reduces the local parasite load of patients with disseminated cutaneous leishmaniasis.

Authors:  H Akuffo; G Kaplan; R Kiessling; S Teklemariam; M Dietz; J McElrath; Z A Cohn
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

4.  Interleukin-2/anti-interleukin-2 monoclonal antibody immune complex suppresses collagen-induced arthritis in mice by fortifying interleukin-2/STAT5 signalling pathways.

Authors:  Seon-Yeong Lee; Mi-La Cho; Hye-Jwa Oh; Jun-Geol Ryu; Min-Jung Park; Joo-Yeon Jhun; Mi-Kyung Park; John C Stone; Ji-Hyun Ju; Sue-Yun Hwang; Sung-Hwan Park; Charles D Surh; Ho-Youn Kim
Journal:  Immunology       Date:  2012-12       Impact factor: 7.397

5.  IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.

Authors:  Samiran Saha; Smriti Mondal; Rajesh Ravindran; Swati Bhowmick; Dolanchampa Modak; Sudeshna Mallick; Mehboobar Rahman; Sourjya Kar; Ramaprasad Goswami; Subhasis Kamal Guha; Netai Pramanik; Bibhuti Saha; Nahid Ali
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

6.  Regulation of Leishmania populations within the host. I. the variable course of Leishmania donovani infections in mice.

Authors:  D J Bradley; J Kirkley
Journal:  Clin Exp Immunol       Date:  1977-10       Impact factor: 4.330

7.  CD4+ natural regulatory T cells prevent experimental cerebral malaria via CTLA-4 when expanded in vivo.

Authors:  Ashraful Haque; Shannon E Best; Fiona H Amante; Seri Mustafah; Laure Desbarrieres; Fabian de Labastida; Tim Sparwasser; Geoffrey R Hill; Christian R Engwerda
Journal:  PLoS Pathog       Date:  2010-12-09       Impact factor: 6.823

Review 8.  The Regulation of CD4(+) T Cell Responses during Protozoan Infections.

Authors:  Christian R Engwerda; Susanna S Ng; Patrick T Bunn
Journal:  Front Immunol       Date:  2014-10-13       Impact factor: 7.561

9.  Blood Transcriptional Profiling Reveals Immunological Signatures of Distinct States of Infection of Humans with Leishmania infantum.

Authors:  Luiz Gustavo Gardinassi; Gustavo Rocha Garcia; Carlos Henrique Nery Costa; Vladimir Costa Silva; Isabel Kinney Ferreira de Miranda Santos
Journal:  PLoS Negl Trop Dis       Date:  2016-11-09

10.  Splenic CD4+ T Cells in Progressive Visceral Leishmaniasis Show a Mixed Effector-Regulatory Phenotype and Impair Macrophage Effector Function through Inhibitory Receptor Expression.

Authors:  Audrie A Medina-Colorado; Elvia Y Osorio; Omar A Saldarriaga; Bruno L Travi; Fanping Kong; Heidi Spratt; Lynn Soong; Peter C Melby
Journal:  PLoS One       Date:  2017-01-19       Impact factor: 3.240

View more
  6 in total

1.  Increased amphiregulin expression by CD4+ T cells from individuals with asymptomatic Leishmania donovani infection.

Authors:  Siddharth Sankar Singh; Shashi Bhushan Chauhan; Susanna Ss Ng; Dillon Corvino; Fabian de Labastida Rivera; Jessica A Engel; Nic Waddell; Pamela Mukhopadhay; Rebecca L Johnston; Lambros T Koufariotis; Susanne Nylen; Om Prakash Singh; Christian R Engwerda; Rajiv Kumar; Shyam Sundar
Journal:  Clin Transl Immunology       Date:  2022-05-27

2.  Single nucleotide polymorphisms of the genes IL-2, IL-2RB, and JAK3 in patients with cutaneous leishmaniasis caused by Leishmania (V.) guyanensis in Manaus, Amazonas, Brazil.

Authors:  Felipe Jules de Araújo Santos; Lener Santos da Silva; José do Espírito Santo Júnior; Tirza Gabrielle Ramos de Mesquita; Mara Lúcia Gomes de Souza; Moacir Couto de Andrade Júnior; Sinésio Talhari; Rajendranath Ramasawmy
Journal:  PLoS One       Date:  2019-08-08       Impact factor: 3.240

3.  Tissue-specific transcriptomic changes associated with AmBisome® treatment of BALB/c mice with experimental visceral leishmaniasis.

Authors:  Sarah Forrester; Karin Siefert; Helen Ashwin; Najmeeyah Brown; Andrea Zelmar; Sally James; Dimitris Lagos; Jon Timmis; Mitali Chatterjee; Jeremy C Mottram; Simon L Croft; Paul M Kaye
Journal:  Wellcome Open Res       Date:  2019-12-10

4.  Unravelling the unsolved paradoxes of cytokine families in host resistance and susceptibility to Leishmania infection.

Authors:  Bernard Ong'ondo Osero; Raphael Taiwo Aruleba; Frank Brombacher; Ramona Hurdayal
Journal:  Cytokine X       Date:  2020-12

5.  Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral Leishmaniasis.

Authors:  Rajiv Kumar; Patrick T Bunn; Siddharth Sankar Singh; Susanna S Ng; Marcela Montes de Oca; Fabian De Labastida Rivera; Shashi Bhushan Chauhan; Neetu Singh; Rebecca J Faleiro; Chelsea L Edwards; Teija C M Frame; Meru Sheel; Rebecca J Austin; Steven W Lane; Tobias Bald; Mark J Smyth; Geoffrey R Hill; Shannon E Best; Ashraful Haque; Dillon Corvino; Nic Waddell; Lambross Koufariotis; Pamela Mukhopadhay; Madhukar Rai; Jaya Chakravarty; Om Prakash Singh; David Sacks; Susanne Nylen; Jude Uzonna; Shyam Sundar; Christian R Engwerda
Journal:  Cell Rep       Date:  2020-02-25       Impact factor: 9.423

6.  Screening Novel Vaccine Candidates for Leishmania Donovani by Combining Differential Proteomics and Immunoinformatics Analysis.

Authors:  Jianhui Zhang; Jiao Li; Kaifeng Hu; Qi Zhou; Xiaoxiao Chen; Jinlei He; Shuangshuang Yin; Yangjian Chi; Xuechun Liao; Yuying Xiao; Hanxiao Qin; Zhiwan Zheng; Jianping Chen
Journal:  Front Immunol       Date:  2022-06-23       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.